Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

ABSTRACT: In this report, we present the case of a 73-year-old male who was seen at Clinic with a 4-month history of persistent cough. The gentleman was an ex-smoker with a 40-pack-year history and ...

Department of Medicine, Mater Dei Hospital, Msida, Malta. In this report, we present the case of a 73-year-old male who was seen at Clinic with a 4-month history of persistent cough. The gentleman was ...

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell ...

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel. Dexamethasone prophylaxis was linked with reduced severity of grade ...

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...

(RTTNews) - Bristol Myers Squibb (BMY), on Tuesday, announced that it has received approval from the European Commission to expand the use of its CAR T cell therapy Breyanzi for relapsed or refractory ...

Bristol Myers Squibb today announced that the European Commission has granted approval to Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

NEW YORK – Lyell Immunopharma on Wednesday said it will pit its autologous CD19/CD20-targeted CAR T-cell therapy rondecabtagene autoleucel (ronde-cel) against currently marketed cell therapies in a ...